Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4R-cembranoid is a naturally occurring **diterpenoid**, specifically a cembranoid isolated from tobacco leaves and flowers. It is characterized by a 14-carbon cembrane ring and has two hydroxyl groups. 4R-cembranoid is notable for its **neuroprotective** and **anti-inflammatory** properties. It has been shown in preclinical studies to protect neurons against various neurotoxic insults (such as NMDA, paraoxon, and diisopropylfluorophosphate) by modulating anti-apoptotic and anti-inflammatory signaling. Its neuroprotection is partly attributed to inhibition of nicotinic acetylcholine receptor subtypes (especially α7 and possibly α4β2 and α3β4), resulting in activation of the PI3-kinase/Akt antiapoptotic pathway. 4R-cembranoid also suppresses neuroinflammation: it inhibits glial pro-inflammatory phenotypes, decreases expression of iNOS, upregulates arginase-1, and reduces microglial/astrocyte activation markers. It can cross the blood-brain barrier rapidly and has a favorable safety profile at experimentally tested doses. Research has focused on its potential for neurodegenerative diseases such as Parkinson’s disease and conditions with neuroinflammatory components[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4R-cembranoid.